Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 Company advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) toward first-in-human studies expected to start in the second half of 2026, significantly expanding the Company's intranasal product portfolio into additional high value therapeutic areas Company well funded through planned NS002 pivotal study and potential NDA submission TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSR
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"),
3 - Nasus Pharma Ltd (0002029039) (Issuer)
3 - Nasus Pharma Ltd (0002029039) (Issuer)
3 - Nasus Pharma Ltd (0002029039) (Issuer)
POS AM - Nasus Pharma Ltd (0002029039) (Filer)
6-K - Nasus Pharma Ltd (0002029039) (Filer)
20-F - Nasus Pharma Ltd (0002029039) (Filer)
TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma's executive leadership team. Mr. Rubin will lead and oversee Nasus Pharma's financial operations, including corporate finance, financial planning, capital strategy, and investor relations, as
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"),
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation. Conference call & webcast info: Monday, March 16, 2026, at 08:00 a.m. ETIndividuals may register for the webcast at